RCS - Roquefort Theraptcs. - Investor Presentation via Engage Investor

Coiled Therapeutics

24/09/2025 07:00

RNS Number : 5229A

Roquefort Therapeutics PLC

24 September 2025

 

24 September 2025

 

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

Investor Presentation via Engage Investor

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, announces that the Company's Chairman Stephen West alongside Edward Painter and Sridhar Vempati, Chairman and Chief Strategy Officer respectively of A2A Pharmaceuticals, Inc. ("A2A Pharma") will host a live interactive presentation on the Engage Investor platform on Monday, 29 September 2025 at 4pm BST.

The objective of the presentation is to provide investors with an update relating to the proposed acquisition of Coiled Therapeutics, Inc. and its AO-252 clinical stage program from A2A Pharma.

All current shareholders and interested investors are invited to join and investors are encouraged to pre-submit questions via the Engage Investor platform. Investors can also submit questions at any time during the live presentation.

Investors can sign up to Engage Investor at no cost and follow Roquefort Therapeutics from their personalised investor hub.

Register interest in this event here:

https://engageinvestor.news/ROQ_IP_0925

ENDS

Enquiries:

Roquefort Therapeutics plc
+44 (0)20 3918 8633
Stephen West (Chairman) / Dr Darrin Disley (Interim MD)
SP Angel Corporate Finance LLP (Broker to the Company)
David Hignell / Vadim Alexandre / Devik Mehta
+44 (0)20 3470 0470
CPS Capital (Broker to A2A Pharmaceuticals)
Jason Peterson / David Valentino
+61 (0)8 9223 2222
Burson Buchanan (Public Relations)
Ben Romney / Jamie Hooper
+44 (0)20 7466 5000
Peak IR (Investor Relations)
Seb Wykeham
+33 (0)7 44 44 15 42

 

LEI: ‎254900P4SISIWOR9RH34

 

For further information on Roquefort Therapeutics, please visit www.roquefortplc.com and @RoquefortTherap on X (formerly Twitter)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
NRAUOUBRVSUKUAR